TranXenoGen, Inc.

Announces Successful Expression of Monoclonal Antibodies in Eggs
Proof of Principle Achieved

TranXenoGen, Inc. ("TranXenoGen" or the "Company"), the avian transgenic company, announces that it has achieved expression of two distinct monoclonal antibodies in the egg white, or albumen, from chimeric chickens. The monoclonal antibodies expressed were the Company's CD4 research antibody and a human antibody of one of its partners.

Monoclonal antibodies represent an important potential new class of drug candidates, the production of which can be difficult and expensive in large quantities. Monoclonal antibodies are complex proteins comprising two light and two heavy chains, which are encoded by two distinct genes. In expressing monoclonal antibodies, the Company has answered an important question; can a protein be expressed in egg white using its transgenic technology. TranXenoGen believes that it is the first to express antibodies in transgenic chicken eggs.

Using an enzyme-linked immunoassay, the antibody expression levels in the chimeric eggs were determined to be up to 1.5 ng/ml. The Company's partner has independently confirmed the expression of the human monoclonal antibody. In addition, the Company screened the CD4 research antibody samples using an immunoflourescent assay with CD4 expressing cells in order to assess antibody function. Positive fluorescent cell staining was observed only on cells expressing CD4 and not in control cells, indicating the antibody bound to its target CD4. Binding is indicative that the monoclonal antibody is correctly assembled, which is a key consideration in producing commercially viable proteins.

The chimeric chickens were developed utilizing a proprietary direct-egg transfection technology for which a patent application has been filed. The direct-egg transfection method is a non-viral gene transfer technique that allows the transfection of large transgene fragments and multiple transgenes simultaneously, which is required for the production of complex proteins such as antibodies. The transgene is injected into the developing chicken embryo to produce a chimeric chicken. The chimeric chicken is bred when mature to generate transgenic founder chickens, which are then screened for expression of the desired protein in their eggs. The direct-egg technology is effective for antibody production, which requires the delivery of two genes to create a whole antibody.

Paul DiTullio, Vice President of Product Development stated:

"This is an important first step in demonstrating the capability of TranXenoGen's technology to produce a monoclonal antibody. The ability of our technology to introduce large DNA fragments with multiple genes into the genome of a chicken egg is key to our focus on the manufacture of high volume monoclonal antibodies. With the achievement of expression at the chimeric stage, the next objective in the development process is to breed fully transgenic chickens to achieve commercial levels of expression. The Company is also developing three additional methodologies, which we believe will improve the efficiency of the transgenic process."

George Uveges, President and CEO commented:

"The achievement of expression of an antibody is a significant step forward in developing our transgenic platform for the production of high volume therapeutics on a cost effective basis. We believe that this is the first reported expression of monoclonal antibodies in transgenic chicken eggs. This result is an important validation that the Company's process of introducing large genes into eggs to produce transgenic chickens works and enables expression of a functional gene product. The development program for which the human antibody expression levels were achieved was with an unnamed U.S. biotechnology company. The original evaluation agreement with that company has expired under its terms, and TranXenoGen has terminated its related research project with that company.

With expression levels achieved at the chimeric stage, we would expect to attain commercial levels of expression at the germline stage within 12 months. We are continuing to develop transgenic chickens for generic biologicals, (Insulin and Human Serum Albumin) and for the other three strategic partners' monoclonal antibody products. Our business development efforts will be focused on obtaining funded commercial collaboration for the development and manufacture of high volume therapeutics."

30 May 2002

Enquiries:

TranXenoGen, Inc. **Tel: 001 508 936 4214**
George Uveges, President and CEO Email: **{** HYPERLINK "mailto:guveges@tranxenogen.com" **}**

College Hill Associates **Tel: 020 7457 2020**
Michael Padley/Nicholas Nelson

Risk Warning Notice:

TranXenoGen,Inc.(symbol TXN.L) is a publicly traded biotechnology company. Its shares are quoted on the Alternative Investment Market of the London Stock Exchange. The Company specializes in avian transgenics for the production of high volume therapeutic proteins. TranXenoGen is a development stage company and, as such, investors should be aware that an investment in the Company involves a substantially high degree of risk.

This press release contains forward-looking statements that can be identified by terminology such us as "expects", "potential", "suggests", "may", "will", or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.